Rebecca Taub - 16 Jan 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Pres., R&D, and CMO, Director
Signature
/s/ Brian J. Lynch**
Issuer symbol
MDGL
Transactions as of
16 Jan 2024
Net transactions value
-$377,100
Form type
4
Filing time
18 Jan 2024, 13:46:51 UTC
Previous filing
18 Jan 2023
Next filing
25 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Tax liability $377,100 -1,546 -9.3% $243.92 15,001 16 Jan 2024 Direct F1, F2
holding MDGL Common Stock 438,212 16 Jan 2024 Direct
holding MDGL Common Stock 655,540 16 Jan 2024 By SQN, LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023.
F2 Represents restricted stock units granted to the Reporting Person on January 16, 2023.
F3 The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

**As attorney-in-fact for Reporting Person